Arsanis gets global rights to panel of RSV antibodies from Adimab

01 Mar 2017

Adimab LLC licensed Arsanis Inc. exclusive worldwide rights to develop and commercialize antibodies aimed at respiratory syncytial virus.

Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)

Already a Biomedtracker subscriber? You have access to the full deal record through your subscription

Want to become a subscriber? Subscribers get more deal details, updates, deal financials and deal products.

Questions?

Please contact Sales at: (212) 520-2765 or email [email protected]

Related Companies

Arsanis gets global rights to panel of RSV antibodies from Adimab

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

DCD.EmailPopout.Notice